Miruvor
Sign up
The short answer

What studies of Alpha-lipoic acid (ALA, R-ALA) found

23papers on Alpha-lipoic acid (ALA, R-ALA)
70people in 2 studies testing Alpha-lipoic acid (ALA, R-ALA) alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Mixed results

Based on the strongest evidence, randomised trials (very low certainty), for smell and taste loss.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies of Alpha-lipoic acid (ALA, R-ALA) for long COVID disagree, so it’s not clear whether it helps. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 23 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Alpha-lipoic acid (ALA, R-ALA) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Smell and taste loss2 studies · 70 people took Alpha-lipoic acid (ALA, R-ALA) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (189 in all); the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 189 people with results

Studies disagree about smell and taste loss.

Studies disagree about whether alpha-lipoic acid (ALA, R-ALA) helps smell and taste loss. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (189 in all)
  • The studies disagree
See the 2 studies
  1. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics. (2024)

    People in the study
    120 randomised · 85 started · 89 analysed
    Dose
    800 mg daily
    Outcome
    resolution of parosmia
    Effect
    worse
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Alpha-lipoic acid does not improve olfactory training results in olfactory loss due to COVID-19: a double-blind randomized trial. (2024)

    People in the study
    128 randomised · 100 analysed
    Dose
    300 mg/pill, 600 mg a day, 01 pill twice a day, for 12-weeks
    Outcome
    CCCRC score Connecticut Chemosensory Clinical Research Center (CCCRC) test
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Studies of combinations

Outcomes that only studies of Alpha-lipoic acid (ALA, R-ALA) given together with other treatments looked at. Shown, not graded: they can’t tell what Alpha-lipoic acid (ALA, R-ALA) did alone.

Fatigue ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): Chalder Fatigue Scale (CFQ), better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Cognition (brain fog) ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): memory, item 11, and problems starting things, item 4, no clear difference.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Depression ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): total MADRS score, no clear difference.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Sleep ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): ISI, better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Overall symptoms ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): CGI-I, better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Combination: Dichloroacetate (DCA) + Thiamine / benfotiamine + CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + L-carnitine35 in the study

Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not? (2018): subjective experience improved (responders) or not (non-reponders), better (not tested).

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Daily functioning ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): WSAS, no clear difference.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Quality of life ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): individual measures of the SF-12, no clear difference.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Autonomic symptoms Long COVID

Combination: Midodrine + Alpha-lipoic acid (ALA, R-ALA) + Nortriptyline (Pamelor) + Exercise (unspecified)152 in the study

Long COVID and the Autonomic Nervous System: The Journey from Dysautonomia to Therapeutic Neuro-Modulation through the Retrospective Analysis of 152 Patients. (2022): average of the 7 P&S dysfunctions after less than 9 months of therapy (pre-COVID-19), better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Overall symptoms Long COVID

Combination: Midodrine + Alpha-lipoic acid (ALA, R-ALA) + Nortriptyline (Pamelor) + Exercise (unspecified)152 in the study

Long COVID and the Autonomic Nervous System: The Journey from Dysautonomia to Therapeutic Neuro-Modulation through the Retrospective Analysis of 152 Patients. (2022): average number of the 28 symptoms at pre-COVID-19 follow-up after autonomic therapy, better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Fatigue Both together

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA)174 in the study

Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. (2023): FSS mean at T1, better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Pain Both together

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA)174 in the study

Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. (2023): VAS pain at T1, better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Sleep Both together

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA)174 in the study

Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. (2023): VAS sleep coefficient (multivariate linear regression), better.

Shown, not counted: Alpha-lipoic acid (ALA, R-ALA) was given together with other treatments.

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    150 to 600 mg at the start in most studies

  2. 2Raise

    Raised step by step in 1 of 5 studies

  3. 3Top dose

    Most often 100 mg (1 of 5 studies)

All papers

  1. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics.2024 · randomised trial · 120 randomised · 85 started · 89 analysed
    Summary

    This randomized clinical trial enrolled 120 patients (30 per group) with persistent COVID-19 parosmia and olfactory loss after prior olfactory training, recruited from the Otolaryngology Unit, University Hospital Federico II of Naples, January 2022 to December 2022. The abstract reports 85 patients randomized; the results report 89 available for analysis. Groups received daily olfactory training (OT) alone (control, n=23 analysed), ultramicronized palmitoylethanolamide plus luteolin (umPEALUT) 1 sachet daily + OT (n=17), alpha-lipoic acid (ALA) 800 mg daily + OT (n=21), or umPEALUT + ALA 600 mg + OT (n=28) for 180 days/6 months. Outcomes were parosmia resolution (primary) and Sniffin’ Sticks TDI score (secondary). Parosmia resolution was 96% combination, 65% control, 53% umPEALUT, 29% ALA (p<0.001). TDI improved in umPEALUT (18.6±10.4 to 29.7±7.5, p<0.01) and combination (19.5±6.3 to 27.5±2.5, p<0.01); control (26.9±5.3 to 27.7±5) and ALA (19.3±5.6 to 21.7±4.3) showed no significant change (p>0.05). No significant difference was found between control and combination at T1 (p>0.05), or control vs ALA and umPEALUT vs combination (p>0.05). 31 were lost to follow-up or discontinued (7 control, 13 umPEALUT, 9 ALA, 2 combination); all regimens were well-tolerated.

  2. Coronavirus disease 2019 related parosmia: an exploratory survey of demographics and treatment strategies.2023 · no comparison group · 214 in the study · 209 with outcome data
  3. Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.2025 · case report · 13 in the study
    Summary

    This patient-led case series documented the impact of extended-course oral nirmatrelvir/ritonavir in 13 individuals with established Long COVID. Participants came from public forums led by and for people with Long COVID or heard about the project by word-of-mouth. They took courses >5 days (range: 7.5–30 days): 11 outside the context of an acute infection (Cases 1–11) and 2 within an acute reinfection (Cases 12–13). There was no comparison group; participants reported symptoms and health experiences before, during, and after treatment. Some outside-acute participants experienced a meaningful reduction in symptoms, although not all benefits persist; others experienced no effect. The discussion states only 5 of the 13 cases experienced sustained improvement. Individual reports included no change, temporary improvement, return to pre-treatment baseline, and recurrence after stopping. One participant stopped early due to intense stomach pain. Reported harms included severe constipation and a severe MCAS flare, a severe “crash,” insomnia and taste-related side effects, dysgeusia, severe stomach pain with discontinuation, itchiness and tingling, dizziness and shakiness, and a PEM crash. For the two participants treated during acute reinfection, both report eventually returning to their pre-re-infection baseline. The authors list limitations: only 13 individuals who may or may not be representative; patient-reported experiences subject to recall or fatigue bias; and substantial heterogeneity in ages, symptoms, and treatment lengths.

  4. HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
    Summary

    This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.

  5. Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome.2023 · combination: given with other treatments · 174 in the study
    Summary

    The Requpero study was a prospective observational study at a post-covid syndrome clinic; of 200 consecutive patients evaluated June 2021 to October 2021, 174 who met inclusion criteria were enrolled. Inclusion required meeting 2015 National Academy of Medicine diagnostic criteria for ME/CFS; patients had chronic COVID syndrome. 116 patients received coenzyme Q10 100 mg bid plus alpha lipoic acid 100 mg bid orally for two months; 58 did not receive any treatment. Both groups received multimodal therapy. Questionnaires were given at baseline (T0) and after 60 days (T1). The primary outcome was FSS response: complete response in 62 (53.5%) treatment patients and two (3.5%) control patients; FSS non-response in 11 treatment (9.5%) and 15 control (25.9%) (p < 0.0001). Mean FSS at T1 was 15.2±8.6 in treatment and 19.7±7.6 in control (p < 0.0001). Similar between-group differences were reported for VAS fatigue, VAS pain, VAS sleep, WPI, FAS and SSS. Harms and withdrawals were not reported. The authors state primary and secondary outcomes were met; limitations include no placebo control, short follow-up, non-validated clinimetric indices, and mitochondrial dysfunction not demonstrated.

  6. Long COVID and the Autonomic Nervous System: The Journey from Dysautonomia to Therapeutic Neuro-Modulation through the Retrospective Analysis of 152 Patients.2022 · combination: given with other treatments · 152 in the study
    Summary

    This retrospective, observational, hypothesis-generating outcomes study asked whether autonomic therapy relates to autonomic function and symptoms in 152 long-COVID patients from two suburban practices in the northeastern United States and from around the world. Patients had pre-existing autonomic dysfunction and had been tested and treated before COVID-19. Treatment components listed were Midodrine 2.5 mg tid, Alpha-Lipoic Acid up to 600 mg tid, Nortriptyline 10 mg qd, and up to 40 minutes of low-and-slow exercise; duration was less than 9 months pre-COVID-19 and less than 6 months of continued post-COVID-19 therapy. There was no comparison group; outcomes were within-patient before/after measures of the average of 7 P&S dysfunctions and average number of 28 symptoms. Pre-COVID-19, the average of 7 P&S dysfunctions was 2.34 at initial presentation and 0.95 at follow-up after less than 9 months (p < 0.001). Post-COVID-19 it was 3.67 and 1.63 after less than 6 months of continued therapy (p = 0.003). The average number of 28 symptoms was 9.74 at pre-COVID-19 baseline and 6.25 at follow-up (p = 0.009); post-COVID-19 it was 14.6 and 7.44 at follow-up (p = 0.004). Side effects and withdrawals were not reported.

  7. News and views in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): The role of co-morbidity and novel treatments.2020 · combination: given with other treatments · 64 in the study
    Summary

    This prospective pragmatic open-label trial enrolled 64 consecutive patients with ME/CFS diagnosed by certified expert university centres who consulted at one author's private clinic. Patients were offered a nutraceutical containing sodium dichloroacetate, Vitamin B1, Alpha lipoic acid, and Ubiquinone Q10; they returned six weeks after intake to complete the FSS again. There was no comparison group. Reported benefit was 32.6% of female patients and 40.0% of male patients; 37% of patients experienced improvement, with an average 33.4% (SD 17.4%) decrease in FSS. After treatment, FSS was 3.96 (SD 0.93) in responders versus 6.13 (SD 0.63) in non-responders (P < 0.001). FSS changed significantly before versus after treatment in responders (P < 0.001), but not in non-responders (P = 0.82). Sixteen patients who did not benefit from DCA received Meldonium 500 mg to 1000 mg per day; 7 patients (44%) reported a positive effect, while another sentence reports six out of 13 patients (46%). One patient interrupted Meldonium because of a feeling of agitation. No DCA harms were reported. The authors state additional investigation is needed to confirm the blood-supply improvement seen in one patient.

  8. Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?2018 · combination: given with other treatments · 35 in the study
    Summary

    In a prospective trial including 35 ME/CFS patients, 25 females and 10 males with mean age 42.5 years (SD 9.6 years) and mean disease duration 8.7 years (SD 4.6 years), patients consulting at the private clinic of the author took one tablet per day of a nutraceutical containing 400 mg of sodium dichloroacetate (DCA) together with vitamin B1, oxidoreductase Ubiquinone Q10, alfa lipoic acid and acetyl-l carnitine. After 4–6 weeks of intake, patients reported their subjective experience as improved (responders, n = 13) or not (non-responders, n = 22) and completed the Fatigue Severity Scale again. There was no separate comparison group; responders were compared with non-responders. In the cohort, 22.9% had auto-immunity with a positive titre of anti-nuclear antibodies (ANA) of 1/80 or more; 25% of that group were responders, compared with 41% of patients without auto-antibodies (difference not significant; P = 0.69). Logistic regression discrimination had an area under the ROC curve = 0.92 (95% confidence interval: 0.78–0.99), P < 0.0001, with specificity of 86% and sensitivity of 84%. Mean fatigue score was 6,00 before and 3,70 after in responders, and 6,23 before and 6,15 after in non-responders. No adverse effects were recorded.

  9. Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial.2018 · combination: given with other treatments · 22 in the study
    Summary

    This open-label, prospective pilot trial treated 22 consecutive patients (14 women, 8 men, mean age 43.3 years, SD: 10,7 years) with refractory and long-lasting ME/CFS, diagnosed by reference centres, with an innovative nutriceutical containing sodium dichloroacetate (DCA). The initial 10 patients received 400 mg of sodium salt of dichloroacetate (DCA) plus 100 mg Vitamin B1, taken one capsule per day for 30 capsules; afterwards the formulation was extended by adding alfa-lipoic acid (ALA), acetyl-l-carnitine and the oxidoreductase ubiquinone Q10. Fatigue was measured with the Fatigue Severity Scale before treatment and after 30 days. Ten patients (45%) responded favourably: their FSS decreased from an average of 6.00 points (SD: 0.68) to 3.48 points (SD: 0.98), a decrease of 42.7% (SD:17.8%; P=0.0001). In the 12 non-responders the FSS was 6.43 points (SD: 0.47) before treatment and 5.96 (SD:1.06) after treatment (P=0.13). In 2 responders with important fibro-myalgic complaints the pain visual scale value decreased from 8 to 2, and from 6 to 2 respectively; responders also noticed important improvement of the cognitive functions, not evaluated by any specific test. One responder experienced generalised moderate tremor, which disappeared immediately after the dose of DCA was decreased. The authors state the trial is open-label with a small number of patients and that the findings need to be challenged by a larger prospective double-blind trial.

  10. Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study2017 · combination: given with other treatments · 10 in the study
    Summary

    This 16-week open-label pilot study examined a combination nutraceutical of mitochondrial agents in 10 patients with chronic fatigue syndrome recruited through clinicians and based at The Melbourne Clinic in Melbourne, Australia. Participants received twice-daily dosing of Co Q10, alpha lipoic acid, N-acetylcysteine, Acetyl L-carnitine, B vitamins and co-factors for 16 weeks, with no placebo comparison. Assessments occurred at baseline, W4, W8, W12 and W16 and included the Chalder Fatigue Scale (CFQ), MADRS, ISI, PGI, CGI-S, CGI-I, WSAS and SF-12. Mean total CFQ scores fell from 22.0 (6.07) at baseline to 12.6 (7.46) at Week 16 (F(4,29) = 6.31, p < 0.001); the baseline-to-Week 4 mean difference was 7.66 (p < 0.01). Nine of 11 CFQ items showed significant improvement, while memory (item 11) and problems starting things (item 4) did not. ISI (p = 0.017) and CGI-I (p = 0.014) improved; MADRS (p = 0.225), PGI (p = 0.33), CGI-S (p = 0.150), WSAS (p = 0.095) and SF-12 measures did not change significantly. Adverse events included headaches/migraines (n = 3), minor gastritis (n = 4), loss of appetite/feeling of fullness (n = 1), brief tachycardia (n = 1) and skin pigmentation on the forehead (n = 1); no serious adverse events were noted, and no participants withdrew due to adverse events. Two participants (20%) withdrew before termination, at week four and week twelve, due to work commitments.

  11. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
    Summary

    Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.

  12. Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome.2007 · combination: given with other treatments · 1 in the study
    Summary

    This case report from Belgium describes one 13-year-old girl with chronic fatigue syndrome (CFS) who was unable to walk or stand and had muscle pain and weakness. She received a combined treatment: antioxidants (L-carnitine, CoQ10, lipoic acid, taurine), a supplement containing L-glutamine, gamma oryzanol and zinc, a specific “leaky gut diet”, and intravenous immunoglobulins (IVIg; sandoglobuline 6 g/day during 1 month, and thereafter 6 g each two weeks for the following months). No comparison group was reported. The paper reports clinical symptoms and serum IgM against the LPS of gram-negative bacteria. During December 2005 to May 2006, no change in the clinical picture could be detected. On August 18, 2006, she regained strength, her concentration was much better and she could read books again, her sleep disorders were much better, and she had restarted swimming classes; she still suffered from non-refreshing sleep and abdominal complaints. On December 8, 2006, her clinical condition was again much better, her sleep became refreshing, and abdominal complaints including bloating were better, although sometimes she had diarrhea and nausea; during one week she had suffered from sore throat and tender lymph nodes. On February 1, 2007, she ascertained that all her symptoms had disappeared. IVIg was stopped, while antioxidants and the leaky gut diet were continued. On July 13, 2007, she finished the school year with a very good score (>80%). By November, 2007, all CFS symptoms were still in remission. No limitations were stated in the supplied text.

  13. Therapeutic effect of anti-neuroinflammatory supplement combined with olfactory training on post-covid olfactory dysfunction: a systematic review and meta-analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis included seven RCTs published between 2021 and 2024, with 525 adults with post-COVID olfactory dysfunction; 332 received PEA-LUT plus olfactory training and 203 received placebo plus olfactory training. The PEA-LUT regimen in the included trials was daily oral PEA 700 mg plus LUT 70 mg with OT, compared with placebo plus OT; average ages ranged from 39.5 to 45.5 years. Outcomes were TDI scores and overall response rate. The pooled TDI score was higher with PEA-LUT plus OT than with OT alone (SMD = 0.90; 95% CI: 0.24–1.58; P < 0.01). The overall response rate was also higher in the combination group (RD = 0.33; 95% CI: 0.01–0.64; P = 0.04). Two studies reported no adverse events in either group; the remaining studies did not report safety outcomes. The authors state that the limited number of RCTs and relatively small sample size constrain generalizability.

  14. Olfactory Training for Post-COVID-19 Olfactory Dysfunction: A Meta-Analysis of Efficacy and Combination Therapies.2025 · systematic review
    Summary

    This systematic review and meta-analysis pooled eight randomized controlled trials of olfactory training for post-COVID-19 olfactory dysfunction; the search covered PubMed, Web of Science, and Ovid Medline through February 2025. The review did not report total participants enrolled or analysed. Training used odors such as lemon, rose, clove, and eucalyptus over a training period, alone or with PEA-luteolin, EDTA nasal spray, corticosteroids, or alpha-lipoic acid; comparators were no treatment, placebo, or alternative therapies. Outcomes were validated smell tests including UPSIT, Sniffin’ Sticks TDI, CCCRC, and B-SIT. PEA-luteolin plus training improved post-intervention olfactory scores versus controls (MD = 4.62, 95% CI: 2.17–7.06, p = 0.0002; I2 = 87%) and recovery rates (RR = 2.02, 95% CI: 1.11–3.68, p = 0.02; I2 = 86%). EDTA plus training improved scores (MD = 2.33, 95% CI: 0.58–4.08, p = 0.009) and recovery (RR = 1.47, 95% CI: 1.03–2.08, p = 0.03). Corticosteroids showed borderline score benefit (MD = 1.34, 95% CI: 0.01–2.67, p = 0.05) but not recovery (RR = 1.19, 95% CI: 0.85–1.68, p = 0.32). Alpha-lipoic acid did not significantly improve scores (MD = 0.50, 95% CI: −0.07–1.07, p = 0.08) or recovery (RR = 1.04, 95% CI: 0.42–2.56, p = 0.93). Overall MD was 3.01 (95% CI: 1.54–4.48, p < 0.0001) and overall RR 1.65 (95% CI: 1.13–2.42, p = 0.01). Side effects were stated for corticosteroids, without counts. No worsening or discontinuation counts were reported. Limitations included varied methodological rigor and small sample sizes.

  15. Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
    Summary

    Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.

  16. The effectiveness of olfactory training for chronic olfactory disorder following COVID-19: a systematic review.2024 · systematic review
    Summary

    This systematic review searched PubMed, Scopus, Web of Science, EBSCOhost and the Cochrane Library through 01 May 2024 for studies of olfactory training in chronic olfactory disorder persisting for 30 days or longer after COVID-19. Fourteen studies (1.596 participants) were included. Olfactory training alone was reported to improve olfactory function in several studies, though Bérubé et al. observed no effect on objective scores while subjective function improved from 3.8 ± 1.9 to 5.4 ± 1.8 (p = 0.002) and parosmia frequency fell from 16 to 14. Khan et al. reported responders in 37.6% of intervention arms versus 24% of controls, and 55% subjective improvement. In Di Stadio et al., 92% of the PEA-LUT group improved versus 42% of controls; mean TDI rose from 20.6 ± 7.9 to 29.8 ± 7.5, and 56% versus 10% reached a normal TDI. With cerebrolysin, recovery was complete in 61.5% and partial in 17%, with no recovery in the group practising olfactory and gustatory training only. Vitamin A plus OT improved BTT scores (MD = 4.4, 95% CI 1.7 to 7.2), while alpha-lipoic acid showed no significant difference in CCCRC score (p = 0.63). Corticosteroid results were conflicting. The review reports minimal side effects. Authors note only 14 studies and single-study evidence for some adjuvants.

  17. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

  18. Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying Biological Mechanisms: Implications for Future Therapeutic Strategies.2025 · review
    Summary

    This review examined overlapping symptoms and mechanisms in Gulf War Illness, fibromyalgia, ME/CFS and long COVID; it did not enrol participants, and no overall setting was reported. It summarised CoQ10 and stem cell evidence. In fibromyalgia, a randomised, double-blind, placebo-controlled study found 300 mg/day of CoQ10 for 40 days significantly reduced chronic pain and fatigue, with improved mitochondrial energy production. In long COVID, a prospective observational study gave 116 patients 200 mg CoQ10 plus 200 mg alpha-lipoic acid per day for 2 months versus 58 placebo patients; fatigue severity was substantially reduced versus placebo. A randomised controlled intervention study of 121 long COVID patients given 500 mg CoQ10 per day for 6 weeks reported no significant benefit on illness symptoms. ME/CFS reports described reduced fatigue and improved quality of life with CoQ10; Castro-Marrero et al. reported CoQ10 plus NADH improved fatigue; an EUROMENE consensus report suggested CoQ10 for fatigue, pain and cognitive dysfunction. Stem cell reports described improvements in sleep, energy, pain and cognitive function in ME/CFS, beneficial effects in severe COVID-19 trials, and symptomatic improvement in a rat fibromyalgia model. No side effects, worsening or withdrawals were reported in the recorded data.

  19. Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
    Summary

    This scoping review asked which therapeutic agents can be used for post-acute sequelae of COVID-19 (PASC). The authors searched PubMed, Embase, and the Cochrane library for English studies published between January 1, 2020, and July 22, 2024; 413 studies were identified and 39 were included. The review did not report a total number of participants. Included reports measured symptoms such as fatigue, pain, cognitive function, olfactory function, pulmonary function, PASC incidence, hospitalization, and death. For metformin, among 1126 patients observed for nine months, 93 (9.3%) reported PASC, with a hazard ratio of 0.59 (95% CI 0.39–0.89; p = 0.012). Low-dose naltrexone showed a hazard ratio of 5.04 for improvement versus physical therapy alone among 108 patients (p = 0.02), and 52–67% of patients in observational studies reported improvements. In a randomized study of 30 patients with PASC and lung fibrosis, nintedanib and pirfenidone improved pulmonary function, 6MWT distance, and oxygen saturation over 12 weeks; nintedanib was associated with diarrhea (80%) and nausea/vomiting (66.6%). The STOP-PASC trial of a 15-day NMV-r course failed to show significant benefit. Ivermectin had no effect on PASC incidence in COVID-OUT, and remdesivir randomized trials showed no clear long-term benefit. The authors state limitations include heterogeneity of PASC symptoms and limited robust evidence.

  20. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  21. Mitochondrial Dysfunction and Coenzyme Q10 Supplementation in Post-Viral Fatigue Syndrome: An Overview.2024 · review
    Summary

    This overview evaluated evidence on mitochondrial dysfunction and CoQ10 supplementation for post-viral fatigue syndrome, including ME/CFS, fibromyalgia, and long COVID. It did not report a single study cohort. The setting and number of included studies were not reported. Instead, it summarized other studies with different designs, including randomised controlled trials and open-label studies, and some compared CoQ10 with placebo. Described CoQ10 studies used 100 mg/day, 150 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, or 500 mg/day, for periods including 40 days, 6 weeks, 8 weeks, 3 months, and 6 months. Reported findings included significant reductions in chronic pain and fatigue in fibromyalgia, and significant improvement in fatigue in adolescent fibromyalgia. In 207 ME/CFS patients, CoQ10 plus 20 mg NADH was reported to significantly improve fatigue perception, health-related quality of life, and sleep quality. In 43 ME/CFS patients, ubiquinol did not improve perceived fatigue, although night-time awakenings improved. A randomised controlled intervention study of 121 long COVID patients reported no significant benefit on chronic COVID-19 symptoms with 500 mg/day CoQ10 for 6 weeks. The review states no serious adverse effects have been reported from clinical studies supplementing CoQ10 in patients with PVFS. The authors conclude that further randomised controlled trials are required to confirm efficacy in ME/CFS and long COVID.

  22. [Evidence map on post-acute COVID-19 sequelae and rehabilitation: Update as of July 2022Mapa de evidencia sobre las secuelas y la rehabilitación tras la COVID-19 aguda: versión actualizada en julio del 2022].2023 · review
    Summary

    This evidence map updated a review of interventions for rehabilitation of post-acute COVID-19 sequelae in people who had symptomatic COVID-19 and post-acute sequelae; the population was predominantly adults. The update searched Biblioteca Virtual em Saúde and PubMed and was dated 27 July 2022. It included 32 review studies. Interventions were grouped as multimodal, pharmacological, therapeutic, and complementary therapies; no single treatment duration was reported. There was no comparison group; the map plotted associations between interventions and health outcomes. Effects were classified as positive, potentially positive, inconclusive, not informed, or no effect. The map reported 166 associations; the update analysed 69 associations. Exercise (isolated, multicomponent, or multimodal) had 23 positive effects and four potentially positive effects. Exercise prescription was reported with positive effects for functional exercise capacity, lung function, and quality of life; exercise had positive effects for mental health, dyspnoea, fatigue, exercise capacity, and muscle strength, while depression was not informed and lung function was absent and functional independence inconclusive. Pharmacological and complementary interventions for sensory functions had 15 associations. No study reported negative or potentially negative effects. Worsening, discontinuation, and side-effect counts were not reported. The authors state the literature remains incipient and many included items were protocols.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime